Zimmer Biomet (NYSE:ZBH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a research report report published on Saturday morning.

Several other analysts have also recently issued reports on ZBH. Stifel Nicolaus set a $110.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price target for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Royal Bank Of Canada dropped their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. Finally, Barclays cut their target price on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $107.33.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $87.42 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. Zimmer Biomet has a 1 year low of $85.33 and a 1 year high of $114.44. The firm has a market capitalization of $17.32 billion, a PE ratio of 21.64, a P/E/G ratio of 2.23 and a beta of 0.62. The business’s 50 day moving average price is $91.57 and its 200-day moving average price is $96.45.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter last year, the firm posted $1.74 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Key Financial Inc boosted its position in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the period. Root Financial Partners LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth $31,000. Finally, Mather Group LLC. acquired a new position in Zimmer Biomet during the 3rd quarter worth $36,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.